Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for halting deadly lung scarring

NCT ID NCT06422884

Ongoing Disease control Sponsor: Endeavor Biomedicines, Inc. Source: ClinicalTrials.gov ↗

Summary

This study is testing whether a new drug called ENV-101 can help slow down lung scarring and improve breathing in adults with idiopathic pulmonary fibrosis (IPF), a serious lung disease. About 213 participants will receive either one of three doses of ENV-101 or a placebo for six months, while continuing their standard medications. Researchers will measure changes in lung function, scarring on scans, and symptoms like cough and shortness of breath to see if the drug works and is safe.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Quilmes, Buenos Aires, B1878FNR, Argentina

  • Research Site

    Buenos Aires, 1888, Argentina

  • Research Site

    Buenos Aires, C1426ABP, Argentina

  • Research Site

    Mendoza, 5501, Argentina

  • Research Site

    Mendoza, CP 5500, Argentina

  • Research Site

    Camperdown, New South Wales, 2050, Australia

  • Research Site

    Macquarie Park, New South Wales, 2109, Australia

  • Research Site

    Brisbane, Queensland, 4032, Australia

  • Research Site

    South Brisbane, Queensland, 4101, Australia

  • Research Site

    Box Hill, Victoria, 3128, Australia

  • Research Site

    Nedlands, Western Australia, 6009, Australia

  • Research Site

    Graz, Styria, 8036, Austria

  • Research Site

    Vienna, 1090, Austria

  • Research Site

    Dinant, Namur, 5500, Belgium

  • Research Site

    Brussels, 1070, Belgium

  • Research Site

    Brussels, 1200, Belgium

  • Research Site

    Edmonton, Alberta, T6G 2C8, Canada

  • Research Site

    Vancouver, British Columbia, V6Z 2K5, Canada

  • Research Site

    Ajax, Ontario, L1S 2J5, Canada

  • Research Site

    Montreal, Quebec, H2X 0A9, Canada

  • Research Site

    Sherbrooke, Quebec, J1H 5N4, Canada

  • Research Site

    Trois-Rivières, Quebec, G8T 7A1, Canada

  • Research Site

    Angers, 49933, France

  • Research Site

    Bordeaux, 33604, France

  • Research Site

    Caen, 14033, France

  • Research Site

    Dijon, 21000, France

  • Research Site

    Montpellier, 34090, France

  • Research Site

    Nantes, 44093, France

  • Research Site

    Paris, 75014, France

  • Research Site

    Paris, 94270, France

  • Research Site

    Rennes, 35033, France

  • Research Site

    Tours, 37044, France

  • Research Site

    Giessen, Hesse, 35398, Germany

  • Research Site

    Immenhausen, Hesse, 34376, Germany

  • Research Site

    Hanover, Lower Saxony, 30625, Germany

  • Research Site

    Essen, North Rhine-Westphalia, 45239, Germany

  • Research Site

    Berlin, 13125, Germany

  • Research Site

    Leipzig, 4103, Germany

  • Research Site

    Dublin, Leinster, D05 AT88, Ireland

  • Research Site

    Dublin, Leinster, D07 A8NN, Ireland

  • Research Site

    Cork, Munster, T12 DC4A, Ireland

  • Research Site

    Dublin, D04 T6F4, Ireland

  • Research Site

    Bologna, Forli-Cesena, 47121, Italy

  • Research Site

    Padua, Padua, 35128, Italy

  • Research Site

    Florence, Tuscany, 50314, Italy

  • Research Site

    Catania, 95123, Italy

  • Research Site

    Milan, 20123, Italy

  • Research Site

    Turin, 10126, Italy

  • Research Site

    Kuala Lumpur, Selangor, 42300, Malaysia

  • Research Site

    Kuala Lumpur, Selangor, 50590, Malaysia

  • Research Site

    Kuala Lumpur, Selangor, 56000, Malaysia

  • Research Site

    Monterrey, Nuevo León, 64060, Mexico

  • Research Site

    Monterrey, Nuevo León, 64718, Mexico

  • Research Site

    San Nicolás de los Garza, Nuevo León, 66465, Mexico

  • Research Site

    San Juan del Río, Querétaro, 76800, Mexico

  • Research Site

    Chihuahua City, 31230, Mexico

  • Research Site

    Mexico City, 14080, Mexico

  • Research Site

    Oaxaca City, 68000, Mexico

  • Research Site

    Puebla City, 72180, Mexico

  • Research Site

    Auckland, New Zealand

  • Research Site

    Christchurch, 8011, New Zealand

  • Research Site

    Hamilton, New Zealand

  • Research Site

    Seoul, (Deogyang District), 10475, South Korea

  • Research Site

    Ulsan, (Dong District), 44033, South Korea

  • Research Site

    Busan, (Haeundae District), 48108, South Korea

  • Research Site

    Seoul, (Seongbuk District), 02841, South Korea

  • Research Site

    Seoul, (Songpa District), 05505, South Korea

  • Research Site

    Seoul, (Yongsan District), 04401, South Korea

  • Research Site

    Seoul, 16499, South Korea

  • Research Site

    Belfast, BT9 7AB, United Kingdom

  • Research Site

    Birmingham, B15 2GW, United Kingdom

  • Research Site

    Birmingham, B9 5SS, United Kingdom

  • Research Site

    Cambridge, CB2 0AY, United Kingdom

  • Research Site

    Edinburgh, EH1 3EG, United Kingdom

  • Research Site

    Exeter, EX2 5DW, United Kingdom

  • Research Site

    Leicester, LE3 9QP, United Kingdom

  • Research Site

    London, SW3 6NP, United Kingdom

  • Research Site

    Londonderry, BT47 6SB, United Kingdom

Conditions

Explore the condition pages connected to this study.

IDIOPATHIC PULMONARY FIBROSIS PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE